<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673218</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025AUS22</org_study_id>
    <nct_id>NCT00673218</nct_id>
  </id_info>
  <brief_title>The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils</brief_title>
  <official_title>The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If you are allergic to ragweed, and not taking certain medications, you will be asked to have
      blood drawn. We will perform experiments on your blood cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult ragweed allergic subjects will have blood drawn. Basophils will be enriched and
      stimulated with allergen and controls. Supernatants from these stimulations will be assayed
      for cytokines and histamine.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Basophil histamine release</measure>
    <time_frame>After 4 weeks treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline injection to match active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xolair</intervention_name>
    <description>150 to 375 mg is administered SC every 2 or 4 weeks</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Omalizumab, rhumab-E25</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 19 to 50

          -  At least 2 year history of ragweed allergic rhinitis

          -  Positive skin prick tests to ragweed &gt;5 mm wheal diameter

          -  IgE &lt;700 iU/m

        Exclusion Criteria:

          -  Use of prohibited medications (e.g. antihistamine in past 7 days and topical or oral
             corticosteroids in past 1 month, beta-agonist or theophylline for 2 days.

          -  History of immunotherapy in the past 2 years

          -  Exposure to Omalizumab in the past 2 years

          -  Clinically significant non-allergic or perennial rhinitis to avoid mediator release
             due to environmental allergens

          -  Asthma other than mild intermittent

          -  Women of childbearing potential who are not on an accepted form of birth control, as
             well as women who are breastfeeding

          -  Known sensitivity to study drug Xolair

          -  Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study

          -  Patients with a previous history of cancer

          -  Use of any other investigational agent in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Townley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL13</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Basophil stimulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

